Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In the randomized dose-expansion phase of a Phase 1 study (NCT03460977), the combination of mevrometostat (1250 mg twice daily on an empty stomach) and enzalutamide (160 mg once daily) demonstrated ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...